Translational Research

For our latest Alum Answers feature, meet Dave Vigerust, PhD’04, who trained as a scientist in Vanderbilt’s IGP umbrella program and then in the Cellular and Molecular Pathology program. He has spent his career interfacing between basic research and the clinic and is now the chief scientific and strategy officer of three companies. Read More

Led by Neil Osheroff, Vanderbilt researchers are the first to undertake a systematic analysis of the mechanism of action of geoptidacin. Gepotidacin is poised to become the first new class of antibacterials to be approved for use in humans in decades. Read More

ASPIRE to Innovate Postdoctoral Fellow Catherine Leasure identifies the issues plaguing drug development. Leasure and Gregor Neuert argue that conventional dose-response studies fail to mirror the complex reality of how drugs behave in the human body. Read More